Prostate cancer: when need testosterone therapy?

Cover Page

Cite item

Full Text

Abstract

The problem of testosterone deficiency (or hypogonadism) remains one of the most urgent in urology. It is known that testosterone deficiency is associated with a decrease in libido, loss of muscle mass and bone mineral density, as well as with the onset of depressive disorders. A low level of testosterone is combined with an increase in insulin resistance, a level of triacylglycerides, an excess body weight. Nevertheless, the appointment of hormone replacement therapy with testosterone is often impossible because of fears of urologists associated with the existence of a hypothesis about certain interrelations between the development of prostate cancer and the level of androgens.

About the authors

S. O Sukhikh

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

Email: docsukhikh@gmail.com
аспирант каф. урологии 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

A. O Vasilyev

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

Email: alexvasilyev@me.com
канд. мед. наук, ассистент каф. урологии 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

A. V Govorov

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

Email: dr.govorov@gmail.com
д-р мед. наук, проф. каф. урологии 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

D. Yu Pushkar

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

Email: pushkardm@mail.ru
чл.-кор. РАН, проф., зав. каф. урологии 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

References

  1. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006; 50 (5): 935.
  2. Fernández-Miró M, Chillarón J.J, Pedro-Botet J. Testosterone deficiency, metabolic syndrome and diabetes mellitus. Med Clin 2016; 146 (2): 69-73.
  3. Lytton B. Prostate cancer: a brief history and the discovery of hormonal ablation treatment. J Urol 2001; 3: 37-8.
  4. Surampudi P.N, Wang C, Swerdloff R. Hypogonadism in the aging male diagnosis, potentials benefits, and risks of testosterone re- placement therapy. Int J Endocrinol 2012; 2 (2): 23-34.
  5. SEER Cancer Statistics Factsheets: Prostate Cancer. National Cancer Institute; Bethesda, MD, USA. Available at: http://seer.cancer.gov/statfacts/html/prost.html
  6. Zhou Y, Bolton E.C, Jones J.O. Androgens and androgen receptor signaling in prostate tumorigenesis. J Mol Endocrinol 2015; 54 (1): 15-29.
  7. Huggins C, Hodges C.V. The effect of castration, of estrogen and of androgen injection on serum phosphatase on metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
  8. Brooke G.N, Bevan C.L. The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 2009; 10 (1): 18-25.
  9. Prehn R.T. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 1999; 59: 4161-4.
  10. DeVore N.M, Scott E.E. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature 2012; 22: 116.
  11. Zhou Y, Otto-Duessel M, He M et al. Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue. J Mol Endocrinol 2013; 51: 143-53.
  12. Traish A.M, Miner M.M, Morgentaler A et al. Testosterone deficiency. Am J Med 2011; 124 (7): 578-87.
  13. Stattin P, Lumme S, Tenkanen L et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Can 2004; 108: 418-24.
  14. Yassin D-J, Manka L, Yassin A et al. Effect of testosterone treatment in hypogonadal men on prostate cancer risk: results of a prospective comparative study - 8 years follow-up analysis to age-matched controls. ASCO Meeting Abstracts 2014.
  15. Agarwal P.K, Oefelein M.G. Testerone replacement therapy after primary treatment for prostate cancer. J Urol 2005; 173: 533-6.
  16. Khera M, Grober E.D, Najari B et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med 2009; 6: 1165-70.
  17. Pastuszak A.W, Pearlman A.M, Lai W.S et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol 2013; 190: 639-44.
  18. Bellefqih S, Hadadi K, Mezouri I et al. Combined radiation therapy and androgen deprivation in the management of prostate cancer: Where do we stand? Cancer Radiother 2016; 8.
  19. Pastuszak A.W, Pearlman A.M, Godoy G et al. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res 2013; 25: 24-8.
  20. Song W, Khera M. Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro. Asian J Androl 2014; 16: 864.
  21. American Cancer Society recommendations for prostate cancer early detection. Available at: https: //www.cancer.org/cancer/prostate-cancer/early-detection/acs-recommendations.html
  22. Khera M, Crawford D, Morales A et al. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol 2014; 65: 115-23.
  23. Kühn C.M, Strasser H, Romming A et al. Testosterone Replacement Therapy in Hypogonadal Men Following Prostate Cancer Treatment: A Questionnaire-Based Retrospective Study among Urologists in Bavaria, Germany. Urol Int 2015; 95: 153-9.
  24. Sarosdy M.F. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007; 109: 536-41.
  25. Balbontin F.G, Moreno S.A, Bley E et al. Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer. BJU Int 2014; 114: 125-30.
  26. Pastuszak A.W, Khanna A, Badhiwala N et al. Testosterone therapy after radiation therapy for low, intermediate, and high risk prostate cancer. J Urol 2015; 194: 1271-6.
  27. Kaplan A.L, Trinh Q.D, Sun M et al. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends. J Sex Med 2014; 11: 1063-70.
  28. Kaplan A.L, Lenis A.T, Shah A et al. Testosterone replacement therapy in men with prostate cancer: a time-varying analysis. J Sex Med 2015; 12: 374-80.
  29. Morgentaler A, Rhoden E.L. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/ml or less. Urology 2006; 68: 1263-7.
  30. Kacker R, Mariam H, San Francisco I.F et al. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian J Androl 2016; 18 (1): 16-20.

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies